LOG IN
SIGN UP
MARKET
XENE
XENE
Xenon Pharmaceut
NASDAQ
Real-time Quotes | Nasdaq Last Sale
26.54
+0.01
+0.04%
After Hours: 26.54 0 0.00% 16:00 05/26 EDT
OPEN
26.33
PREV CLOSE
26.53
HIGH
27.00
LOW
25.73
VOLUME
469.21K
TURNOVER
0
52 WEEK HIGH
36.42
52 WEEK LOW
14.65
MARKET CAP
1.41B
P/E (TTM)
-15.8903
1D
5D
1M
3M
1Y
5Y
Recap: Xenon Pharmaceuticals Q1 Earnings
Xenon Pharmaceuticals (NASDAQ:XENE) reported its Q1 earnings results on Tuesday, May 10, 2022 at 04:00 PM. Here's what investors need to know about the announcement.
Benzinga · 05/10 21:57
Xenon Pharmaceuticals (XENE) Reports Q1 Loss, Misses Revenue Estimates
Xenon Pharmaceuticals (XENE) delivered earnings and revenue surprises of 7.89% and 4.92%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/10 21:45
BRIEF-Xenon Pharmaceuticals Reports Q1 Results
reuters.com · 05/10 20:08
Xenon Pharmaceuticals Q1 EPS $(0.35) Beats $(0.41) Estimate, Sales $8.77M Beat $8.70M Estimate
Xenon Pharmaceuticals (NASDAQ:XENE) reported quarterly losses of $(0.35) per share which beat the analyst consensus estimate of $(0.41) by 14.63 percent. This is a 16.67 percent increase over losses of $(0.42) per share
Benzinga · 05/10 20:08
Xenon Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
XEN1101 “End of Phase 2” Meeting with FDA to take Place in Second Quarter and Initiation of Phase 3 in Adult Focal Epilepsy Expected in the Second Half of 2022 Company-sponsored Phase 2 Clinical Trial Initiated to Evaluate XEN1101 for the Treatment of MDD ...
GlobeNewswire · 05/10 20:01
Xenon Pharmaceuticals Q1 Loss Narrows, Revenue Rises
MT Newswires · 05/10 16:28
-- Earnings Flash (XENE) XENON PHARMACEUTICALS Posts Q1 Revenue $8.8M, vs. Street Est of $7.74M
MT Newswires · 05/10 16:12
The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves
Here's a roundup of top developments in the biotech space over the last 24 hours:
Benzinga · 05/10 13:23
No Data
Learn about the latest financial forecast of XENE. Analyze the recent business situations of Xenon Pharmaceut through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating
Based on 10 analysts
Strong Buy
Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.
60.00%Strong Buy
40.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average XENE stock price target is 45.00 with a high estimate of 50.00 and a low estimate of 40.00.
Current 26.54
EPS
Actual
Estimate
-0.41-0.31-0.20-0.10
Institutional Holdings
Institutions: 155
Institutional Holdings: 52.49M
% Owned: 98.84%
Shares Outstanding: 53.11M
TypeInstitutionsShares
Increased
48
3.62M
New
20
2.69M
Decreased
40
4.34M
Sold Out
15
423.26K
- Performance
- Asset Allocation
- Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.99%
Pharmaceuticals & Medical Research
+0.43%
Key Executives
Chairman/Executive Director
Simon Pimstone
President/Chief Executive Officer/Chief Operating Officer
Ian Mortimer
Chief Financial Officer
Sherry Aulin
Executive Vice President
James Empfield
Executive Vice President
Robin Sherrington
Other
Christopher Von Seggern
Lead Director/Independent Director
Dawn Svoronos
Independent Director
Mohammad Azab
Independent Director
Clarissa Desjardins
Independent Director
Steven Gannon
Independent Director
Michael Hayden
Independent Director
Frank Holler
Independent Director
Patrick Machado
Independent Director
Gary Patou
No Data
No Data
About XENE
Xenon Pharmaceuticals Inc. is a clinical stage biopharmaceutical company. The Company is engaged in developing therapeutics in patients with neurological disorders. Its product candidates include XEN1101, XEN496 and XEN007. Its partnered programs include NBI-921352 and FX301. Its XEN1101is a Kv7 potassium channel modulator for the treatment of epilepsy and other neurological disorders. Its XEN496 is a Kv7 potassium channel modulator for the treatment of KCNQ2 developmental and epileptic encephalopathy (KCNQ2-DEE). Its XEN007 is a CNS-acting Cav2.1 and T-type calcium channel modulator that for the treatment of childhood absence epilepsy (CAE). The NBI-921352 is a Nav1.6 sodium channel inhibitor to treat pediatric patients with SCN8A developmental and epileptic encephalopathy (SCN8A-DEE) and other indications, including adult focal epilepsy.
Webull offers kinds of Xenon Pharmaceuticals Inc stock information, including NASDAQ:XENE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, XENE stock news, and many more online research tools to help you make informed decisions.
You can practice and explore trading XENE stock methods without spending real money on the virtual paper trading platform.